116. Management of low-risk gestational trophoblastic tumors with etoposide in patients resistant to methotrexate
Estratto da: Advances on Gynaecological Oncology. Knokke (Belgio), 9-12 Maggio 1995
( in coll. G. Mangili, E. Garavaglia, M. Dindelli, G. Candotti, A. Ferrari )
Summary: Methotrexate (MTX) appears now the best initial therapy for patients with low-risk Gestational Trophoblastic Tumors (GTT). About 20-50% of low-risk gestational trophoblastic cases will require alternative chemiotherapeutic agents in order to achieve remission because of resistance.Twelve patients resistent to MTX from 1987 to 1993 were treated with 100 mg/m2 VP16 e.v. for 5 consecutive days every 10 days. In patients with lung metastases we executed endorachis administrations of MTX. All patients achieved sustained gonadotropin remission after chemotherapy with VP16(mean 5 courses).
